Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale

Christopher Cao, Tristan D. Yan, David L. Morris, Kurt Van Der Speeten, Søren Laurberg, Olivier Glehen, Karl Link, Pompiliu Piso, Antonios Apostolos K. Tentes, Marcello Deraco, Stein G. Larsen, Dragutin Kecmanovic, Luis G. Bayón, Juan T. Melero, Santiago González-Moreno, Haile Mahteme, Philippe Gertsch, Brendan Moran, Jesus Esquivel, Richard AlexanderEdward A. Levine, Paul H. Sugarbaker

Research output: Contribution to journalShort surveypeer-review

2 Scopus citations


Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive and rare form of cancer arising from the mesothelial lining of the peritoneum. Due to the latency period between asbestos exposure and disease progression, the peak in incidence of DMPM is likely to occur in the coming decade for many industrialized nations, with a multitude of industrial, medico-legal and health-related implications1,2. Traditional therapeutic modalities such as systemic chemotherapy and radiotherapy have not been proven to be effective in the treatment of DMPM, and patients diagnosed with the disease have a life expectancy of less than 12 months3-5. Combined treatment involving cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been utilized in several specialized centers around the world and has been found to be a feasible procedure with encouraging survival outcomes6-8.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
Issue number1
StatePublished - Jan 2012
Externally publishedYes


  • Cytoreductive surgery
  • Peritoneal mesothelioma
  • Peritonectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale'. Together they form a unique fingerprint.

Cite this